Cell type–specific gene therapy confers protection against motor neuron disease caused by a TFG variant
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2410996121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Molly M Lettman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomolecular Chemistry, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705. Hauptthemen laut MEDLINE: Motor Neuron Disease, Genetic Therapy, Disease Models, Animal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of General Medical Sciences (NIGMS), NIGMS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Inherited forms of motor neuron disease (MND), including hereditary spastic paraplegias (HSP), are associated with the death or dysfunction of nerve cells that control skeletal muscle activity. However, in some cases, the impacts of genetic variants underlying MND act in a non–cell autonomous manner, instead affecting the function of other cell types necessary for neuronal maintenance. Pathological mutations in TFG, which have been implicated in HSP, lead to axonopathy within the corticospinal tract, but it remains unclear whether this problem arises due to perturbations within neurons or supporting neuroglia. To address this question, we leveraged a rat model harboring the recessive TFG p.R106C mutation (mRATBN7.2, g.11:43897639C>T, c.316C>T), which recapitulates multiple phenotypes associated with HSP in humans, including progressive motor deficits, leg spasticity, and indications of an inflammatory response within the motor cortex. In particular, we took advantage of cell type–specific gene therapies to demonstrate that the reintroduction of wild-type TFG into synapsin 1-positive neurons provides robust protection against MND, whereas its expression in GFAP-positive glial cells provides no significant improvement in quantitative measures of gait, despite a dramatic reduction in the presence of reactive astrocytes throughout the brain. These data strongly suggest that therapeutic approaches targeting neurons should be pursued in cases of TFG-HSP, with our animal model offering a unique platform for preclinical assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomolecular Chemistry, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705.
- Department of Chemistry, University of Wisconsin, Madison, WI 53706.
- National Center for Quantitative Biology of Complex Systems, University of Wisconsin, Madison, WI 53706.
- Morgridge Institute for Research, Madison, WI 53715.
ORCID-Profile: Molly M Lettman, Emma Burkard, James R Alvin, Joshua J Coon, Anjon Audhya
Förderung
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- NIGMS NIH HHS
- NICHD NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- NCI NIH HHS
- HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NINDS NIH HHS
Zitieren
APA
Lettman, M. M., Mendina, C. A., Burkard, E., Alvin, J. R., Zhu, Y., Coon, J. J., & Audhya, A. (2024). Cell type–specific gene therapy confers protection against motor neuron disease caused by a TFG variant. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2410996121
Vancouver
Lettman MM, Mendina CA, Burkard E, Alvin JR, Zhu Y, Coon JJ, et al. Cell type–specific gene therapy confers protection against motor neuron disease caused by a TFG variant. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2410996121
BibTeX
@article{Lettman2024,
author = {Lettman, Molly M and Mendina, Caitlin A and Burkard, Emma and Alvin, James R and Zhu, Yunyun and Coon, Joshua J and Audhya, Anjon},
title = {Cell type–specific gene therapy confers protection against motor neuron disease caused by a TFG variant},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2410996121}
}
EUVIMED